Article
Oncology
Gang Xiao, Lifeng Li, Guilong Tanzhu, Zhiyuan Liu, Xuan Gao, Xin Wan, Desheng Xiao, Liu Chen, Xuefeng Xia, Rongrong Zhou
Summary: This study found that lung adenocarcinomas (LUAD) with EGFR-positive and ALK-positive had a suppressive tumor immune microenvironment (TIME) and were less responsive to immunotherapy. The TIME in patients with EGFR/ALK-positive LUAD brain metastases (BMs) was different from that in primary lung cancer. Evaluating the immune characteristics of LUAD BMs is important for clinical treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Jan Budczies, Martina Kirchner, Klaus Kluck, Daniel Kazdal, Julia Glade, Michael Allgaeuer, Mark Kriegsmann, Claus-Peter Heussel, Felix J. Herth, Hauke Winter, Michael Meister, Thomas Muley, Torsten Goldmann, Stefan Froehling, Martin Wermke, Cornelius F. Waller, Amanda Tufman, Martin Reck, Solange Peters, Peter Schirmacher, Michael Thomas, Petros Christopoulos, Albrecht Stenzinger
Summary: The study found specific immunosuppressive characteristics in ALK- and EGFR-positive lung adenocarcinoma, supporting further clinical evaluation of immune-modulators as partners of immune checkpoint blockade in such tumors. The targeted gene expression profiling is a promising tool to analyze tumor microenvironment characteristics from routine diagnostic lung cancer biopsies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Multidisciplinary Sciences
Xiaoyu Han, Jun Fan, Yumin Li, Yukun Cao, Jin Gu, Xi Jia, Yuhui Wang, Heshui Shi
Summary: This study aimed to identify the relationships of EGFR mutations and ALK status with CT characteristics in adenocarcinoma using a large patient cohort. The most significant independent prognostic factors of EGFR effective mutations were female sex, nonsmoker status, GGO air bronchograms, and pleural retraction. The use of CT features in combination with clinical variables showed superiority in predicting ALK positivity compared to using clinical variables alone.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
Mercedes Herrera-Juarez, Cristina Serrano-Gomez, Helena Bote-de-Cabo, Luis Paz-Ares
Summary: Precision oncology aims to design the best cancer treatment based on tumor biology. In NSCLC, patients with actionable genomic aberrations can benefit from targeted therapy, such as EGFR mutations and ALK rearrangements. Effective inhibitors have been developed for various druggable targets, leading to a paradigm shift in NSCLC treatment.
Article
Medicine, General & Internal
Hongbiao Wang, Sujuan Zhu, Zhifeng Li, Xiaofang Qi, Liwen Zhang, Leiyu Ke, Yingcheng Lin
Summary: This study found differential sensitivities to tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma patients with EGFR mutations and ALK rearrangements, suggesting the efficacy of alectinib in this patient population. The results of this study are clinically significant for precision therapy in lung adenocarcinoma patients.
Article
Pharmacology & Pharmacy
Haoyue Hu, Songtao Tan, Meng Xie, Peng Guo, Qiang Yu, Juan Xiao, Kangrui Zhao, Qiong Liao, Yi Wang
Summary: In non-small cell lung cancer, concurrent genetic alterations of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are rare, but their clinical and pathological characteristics are not well-defined, and the optimal treatment approach remains controversial. This report presents a case of stage IV lung adenocarcinoma with both EGFR and ALK mutations, along with high PD-L1 expression. The patient initially received treatment with EGFR tyrosine kinase inhibitors (TKIs), but the disease progressed, and regression was achieved following a switch to ALK-TKI therapy and local radiotherapy. Our report also provides a comprehensive summary of the clinical and pathological features, as well as treatment strategies, for NSCLC patients with concurrent EGFR mutation and ALK rearrangement.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Yaping Zhang, Hui Wang, Xiaoyan Wang, Shuai Li, Hongming Fang
Summary: EGFR, ALK, and ROS1 mutations are typically considered mutually exclusive. This article describes a rare case of a patient with triple mutations in EGFR, ALK, and ROS1 in advanced NSCLC, who responded well to multiple treatment options with a slightly poorer overall survival than patients with single driver gene mutations.
CLINICAL LUNG CANCER
(2021)
Article
Biotechnology & Applied Microbiology
Hironori Satoh, Yusuke Okuma, Jumpei Kashima, Aya Konno-Yamamoto, Yasushi Yatabe, Yuichiro Ohe
Summary: This case report described a 32-year-old female patient with ALK-rearranged non-small cell lung cancer presenting with miliary pulmonary metastasis and elevated serum amylase level. Treatment with alectinib resulted in regression of CT findings and decrease in serum amylase level. It emphasizes the importance of comprehensive driver mutation testing in young patients with miliary pulmonary metastasis.
ONCOTARGETS AND THERAPY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Lan Song, Zhenchen Zhu, Huanwen Wu, Wei Han, Xin Cheng, Ji Li, Huayang Du, Jing Lei, Xin Sui, Wei Song, Zheng-yu Jin
Summary: The study developed a nomogram to identify ALK mutations in lung adenocarcinoma patients, incorporating clinical, CT, PET/CT, and histopathological features. The integrated model showed good performance in training and validation cohorts. Histopathological features were found to enhance the predictive ability of the model, demonstrating the potential for the nomogram as a non-invasive tool for assessing ALK rearrangement in lung adenocarcinoma.
EUROPEAN RADIOLOGY
(2021)
Article
Peripheral Vascular Disease
Hengqiu He, Wendi Yang, Yusheng Huang, Xiaoyue Zhang, Yuan Peng, Zhenzhou Yang
Summary: This case study highlights the significance of using antiangiogenic therapy combined with chemotherapy in achieving sustained remission in advanced lung adenocarcinoma patients with concurrent ALK/EGFR mutations and extremely high PD-L1 expression. The use of anti-angiogenics should not be underestimated in this era of targeted therapy and checkpoint inhibitors.
Article
Oncology
Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Shinsaku Tokuda, Kenji Morimoto, Soichi Hirai, Yohei Matsui, Ryota Nakamura, Masaki Ishida, Hayato Kawachi, Kazue Yoneda, Kazutaka Hosoya, Takahiro Tsuji, Hiroaki Ozasa, Akihiro Yoshimura, Masahiro Iwasaku, Young Hak Kim, Mano Horinaka, Toshiyuki Sakai, Takahiro Utsumi, Shinsuke Shiotsu, Takayuki Takeda, Ryohei Katayama, Koichi Takayama
Summary: In this study, it was found that epidermal growth factor receptor (EGFR) signaling is involved in adaptive resistance to lorlatinib in ALK-rearranged NSCLC. EGFR inhibition enhanced ALK inhibition-induced apoptosis and halted the proliferation of ALK-rearranged lung cancer cells. Combination therapy with EGFR inhibitor and lorlatinib significantly suppressed tumor regrowth after cessation of treatment. This study provides new insights into tumor evolution and the development of combined therapeutic strategies for ALK-rearranged lung cancer.
NPJ PRECISION ONCOLOGY
(2023)
Article
Respiratory System
Xiaolu Ren, Xiaolian Wen, Yue-Jun Ren, Xiang Liu, Jian Wang, Mingyan Hao, Qiang Ma, Jiwei Ron, Baoli Jin, Xiaoyuan Qiao, Bo Li, Jing Wu, Xiaomin Li, Zhihong Liu
Summary: The positive expression of TTF-1 and Napsin A has significant prompting value for EGFR mutations in patients with LUAD, and can be combined with other clinical characteristics to enhance the prediction of EGFR status.
JOURNAL OF THORACIC DISEASE
(2022)
Article
Oncology
Qian Zeng, Han Gao, Longdan Zhang, Shouming Qin, Yongyao Gu, Quanfang Chen
Summary: The study found a patient with EGFR-resistant mutant lung cancer who developed a double-fusion EML4-ALK and STRN-ALK variant after gefitinib treatment, but a combined therapeutic regimen of crizotinib plus osimertinib showed a promising prognosis, confirmed with disappearance of some genes in subsequent genotype testing.
Article
Oncology
Yixiang Zhu, Ye Zhang, Xingsheng Hu, Mingzhao Wang, Hongyu Wang, Yutao Liu
Summary: ICI combined with chemotherapy +/- bevacizumab may be an effective and safe treatment option for EGFR/ALK-positive NSCLC patients, especially for those who progress after previous TKI therapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Cell Biology
Fabien Forest, David Laville, Cyril Habougit, Vanessa Da Cruz, Francois Casteillo, Violaine Yvorel, Sandrine Bard-Sorel, William Godard, Tiphanie Picot, Olivier Tiffet, Jean-Luc Perrot, Michel Peoc'h
Summary: The study analyzed 42 lung adenocarcinoma skin metastasis samples collected between 2010 and 2020 from a database of 2659 lung adenocarcinomas. The results showed that skin metastases of lung adenocarcinoma have a specific histopathological profile, indicating differences from other metastatic sites.
Article
Oncology
Dalyong Kim, Shin Hye Yoo, Seyoung Seo, Hyun Jung Lee, Min Sun Kim, Sung Joon Shin, Chi-Yeon Lim, Do Yeun Kim, Dae Seog Heo, Chae-Man Lim
Summary: This study analyzed the decision-making patterns for life-sustaining treatment (LST) and medical service utilization changes after the enforcement of the Life-Sustaining Treatment Decision-Making Act. The results showed that the cancer patient's own decision-making was associated with earlier decision-making, less use of certain critical treatments, and lower medical costs.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Chaelin Lee, Miso Kim, Dong-Wan Kim, Tae Min Kim, Soyeon Kim, Sun-Wha Im, Yoon Kyung Jeon, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo
Summary: This study reveals that the T790M mutation in EGFR-KDD confers resistance to 1st and 2nd generation EGFR tyrosine kinase inhibitors (TKIs), but is sensitive to 3rd generation EGFR TKIs. In addition, the study identifies that the C797S mutation in kinase domain 2 of EGFR-KDDT790M mediates a resistance mechanism against 3rd generation EGFR TKIs.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Manish A. Shah, Kohei Shitara, Florian Lordick, Yung-Jue Bang, Niall C. Tebbutt, Jean-Phillippe Metges, Kei Muro, Keun-Wook Lee, Lin Shen, Sergei Tjulandin, John L. Hays, Naureen Starling, Rui-Hua Xu, Keren Sturtz, Marilyn Fontaine, Cindy Oh, Emily M. Brooks, Bo Xu, Wei Li, Chiang J. Li, Laura Borodyansky, Eric Van Cutsem
Summary: Adding napabucasin to paclitaxel did not improve survival in patients with second-line advanced gastric or gastroesophageal junction adenocarcinoma. The safety profile of napabucasin was driven by manageable gastrointestinal events, with grade >= 3 diarrhea occurring at a higher frequency with napabucasin plus paclitaxel versus placebo plus paclitaxel.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Sehhoon Park, Chan-Young Ock, Hyojin Kim, Sergio Pereira, Seonwook Park, Minuk Ma, Sangjoon Choi, Seokhwi Kim, Seunghwan Shin, Brian Jaehong Aum, Kyunghyun Paeng, Donggeun Yoo, Hongui Cha, Sunyoung Park, Koung Jin Suh, Hyun Ae Jung, Se Hyun Kim, Yu Jung Kim, Jong-Mu Sun, Jin-Haeng Chung, Jin Seok Ahn, Myung-Ju Ahn, Jong Seok Lee, Keunchil Park, Sang Yong Song, Yung-Jue Bang, Yoon-La Choi, Tony S. Mok, Se-Hoon Lee
Summary: This study developed an AI-powered WSI analyzer of tumor-infiltrating lymphocytes (TIL) to predict the effectiveness of immune checkpoint inhibitors (ICI). The results showed that the inflamed immune phenotype (IP) correlated with enrichment in local immune cytolytic activity, higher response rate, and prolonged progression-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Keun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, Charles S. Fuchs, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo R. Castro, Joseph Chao, Zev A. Wainberg, Z. Alexander Cao, Deepti Aurora-Garg, Julie Kobie, Razvan Cristescu, Pooja Bhagia, Sukrut Shah, Josep Tabernero, Kohei Shitara, Lucjan Wyrwicz
Summary: This analysis of KEYNOTE-062 suggests an association between tumor mutational burden (TMB) and clinical efficacy with first-line pembrolizumab-based therapy in patients with advanced gastric/gastroesophageal junction adenocarcinoma. However, the clinical utility of TMB was attenuated after excluding patients with MSI-H tumors.
CLINICAL CANCER RESEARCH
(2022)
Article
Infectious Diseases
Jeong-Han Kim, Shin Hye Yoo, Bhumsuk Keam, Dae Seog Heo
Summary: Palliative care consultation may reduce aggressive antibiotic use in hospitalized patients with terminal cancer during the end-of-life phase.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Oncology
Jeongjae Lee, Bhumsuk Keam, Ha-Ram Park, Ji-Eun Park, Soyeon Kim, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Summary: This study found a correlation between HLA-E surface expression in head and neck squamous cell carcinoma cell lines and the efficacy of the NKG2A inhibitor, monalizumab, in promoting NK cell activity. Cell lines with high HLA-E expression showed stronger inhibition of NK cell cytotoxicity and had higher efficacy of monalizumab. Combination with cetuximab increased the effectiveness of monalizumab. Stimulation of isolated NK cells with IL-2 and IL-15 also increased the efficacy of monalizumab, even in the HLA-E low groups.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun-Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara
Summary: This study aimed to investigate the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-low gastric or gastroesophageal junction adenocarcinoma. The results showed that T-DXd has clinical activity in heavily pretreated patients with HER2-low gastric/GEJ adenocarcinoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jeongjae Lee, Bhumsuk Keam, Soyeon Kim, Jung-Nyoung Heo, Eunkyo Joung, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo
Summary: A novel GCN2 inhibitor, AST-0513, was found to inhibit the GCN2-ATF4 pathway, reduce proliferation, induce cell cycle arrest and apoptosis in head and neck squamous cell carcinoma cell lines, suggesting its potential as a therapeutic option.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, Katrin M. Sjoquist, Andrew J. Martin, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Li-Tzong Chen, Markus Moehler, Tanios Bekaii-Saab, Thierry Alcindor, Christopher J. O'Callaghan, Niall C. Tebbutt, Wendy Hague, Howard Chan, Sun Young Rha, Keun-Wook Lee, Val Gebski, Anthony Jaworski, John Zalcberg, Timothy Price, John Simes, David Goldstein
Summary: This study aims to evaluate the efficacy and safety of regorafenib alone and in combination with nivolumab in advanced gastro-oesophageal cancer patients. The study consists of two international randomized controlled trials, comparing the efficacy of regorafenib versus placebo, and the efficacy of regorafenib plus nivolumab versus chemotherapy. The primary endpoint of the study is overall survival.
Article
Medicine, General & Internal
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A. Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani
Summary: Zolbetuximab in combination with mFOLFOX6 significantly prolongs progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, with good safety profile.
Article
Biochemistry & Molecular Biology
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Summary: This study is a phase 2 basket trial evaluating the efficacy and safety of dabrafenib plus trametinib in patients with BRAFV600E-mutated advanced rare cancers. The overall response rates in different tumor types ranged from 56% to 89%. Secondary endpoints included duration of response, progression-free survival, overall survival, and safety.
Article
Oncology
Fortunato Ciardiello, Yung-Jue Bang, Andres Cervantes, Mikhail Dvorkin, Charles D. Lopez, Jean-Philippe Metges, Antonio Sanchez Ruiz, Mariona Calvo, Andrew H. Strickland, George Kannourakis, Kei Muro, Hisato Kawakami, Jia Wei, Christophe Borg, Zhaoyin Zhu, Neal Gupta, Robert J. Pelham, Lin Shen
Summary: The study investigated the efficacy and safety of maintenance therapy with Pamiparib in gastric cancer. The results showed that Pamiparib did not demonstrate a significant superiority in progression-free survival (PFS) compared to placebo, but it was well tolerated with few adverse events.
Article
Biochemistry & Molecular Biology
Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, Yung-Jue Bang, Peter Enzinger, David Ilson, Florian Lordick, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Haci Mehmet Turk, Mok Oh, Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Rui-Hua Xu
Summary: The GLOW trial demonstrated that zolbetuximab, a monoclonal antibody targeting CLDN18.2, combined with CAPOX, significantly improved progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Meeting Abstract
Oncology
S. Park, T. M. Kim, S. Kim, M. Kim, B. Keam, D. W. Kim, D. S. Heo
EUROPEAN JOURNAL OF CANCER
(2022)
